CAI - Company ID 0002019410
The table below shows Caris Life Sciences, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | - | - | $819.90M | $753.22M | $718.93M |
| Short-term investments | $102.06M | $102.20M | $2.31M | $2.27M | $2.25M |
| Receivables | $133.32M | $116.89M | $90.52M | $26.70M | $50.89M |
| Inventory | - | - | - | - | - |
| Total current assets | $1.07B | $1.06B | $1.01B | $854.25M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $833.32M |
| Property, plant & equipment | $102.30M | $95.72M | $82.67M | $64.00M | $61.31M |
| Goodwill | $19.34M | $19.34M | $19.34M | $19.34M | $19.34M |
| Total assets | $1.26B | $1.23B | $1.16B | $984.57M | $955.06M |
| Accounts payable | $63.84M | $85.99M | $69.80M | $29.00M | $28.73M |
| Total current liabilities | $158.95M | $191.44M | $143.90M | $86.03M | $90.18M |
| Long-term debt | $393.18M | $392.97M | $381.40M | $376.30M | $373.61M |
| Total liabilities | $616.14M | $637.89M | $568.90M | $506.21M | $502.15M |
| Retained earnings | -$2.53B | -$2.55B | -$2.55B | -$2.63B | -$2.66B |
| Total equity | $639.48M | $591.73M | $593.49M | $478.36M | $452.90M |